Last reviewed · How we verify
PriorixTM
Priorix is a live attenuated combination vaccine that stimulates immune responses against measles, mumps, and rubella viruses.
Priorix is a live attenuated combination vaccine that stimulates immune responses against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.
At a glance
| Generic name | PriorixTM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Live attenuated viral vaccine |
| Target | Measles virus, mumps virus, rubella virus |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Priorix contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in vaccinated individuals without causing disease, thereby triggering both humoral and cellular immune responses. This leads to the production of protective antibodies and memory immune cells against all three viral pathogens. The vaccine provides long-term immunity against measles, mumps, and rubella infections.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Rash
- Parotitis (mumps-like symptoms)
- Arthralgia/arthritis
Key clinical trials
- Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children (PHASE3)
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM (PHASE3)
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PriorixTM CI brief — competitive landscape report
- PriorixTM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI